3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Apogee Acquisition Corp said errors in its June 30, 2026 quarterly report require a restatement of the financial statements, which should no longer be relied upon, with Amendment No. 1 to be filed October 16, 2026. The company also disclosed that director Anna Brunelle and COO Tom Watson have resigned, which affects board and officer staffing.
Errors involve the portion of private placement unit proceeds contributed to the trust account, plus the number of private placement units, Class A shares subject to redemption, and warrants.
Audit committee concluded on October 14, 2026 that the Q2 10-Q should be restated and no longer relied upon.
Anna Brunelle resigned from the Board, audit committee and compensation committee, effective October 13, 2026.
Tom Watson resigned as Chief Operating Officer, effective October 14, 2026; Christopher Valentine was appointed to the audit committee.
GoPro said its previously issued financial statements for fiscal 2025, the third quarter of 2025, and the first two quarters of 2026 should no longer be relied upon because of errors in accounting for debt instruments, including warrants issued to Mateo Financing and convertible debentures issued to YA II PN. The company identified a material weakness in internal control over financial reporting and plans to file restated amended reports. The filing says revenue, gross margin, operating loss, cash, and operating cash flows were not affected, but net loss was.
Audit Committee concluded on October 9, 2026 that the 2025 audited statements, the Q3 2025 statements, and the 2026 quarterly statements are materially misstated and should not be relied upon.
Warrant liability was understated, and long-term debt overstated, by $8.1 million at initial measurement on August 4, 2025.
Convertible debenture embedded conversion derivative of $30.9 million was initially recorded incorrectly, with the errors affecting interest expense and other income (expense).
Restated filings planned include a 2025 10-K/A, a Q1 2026 10-Q/A, and a Q2 2026 10-Q/A, with management's internal control report for 2025 also to be updated.
On October 16, 2026, Cipher Digital issued $850.0 million of 0.00% convertible senior notes maturing November 1, 2032, with a 13-day option for initial purchasers to buy up to $150 million more. The company also entered capped call transactions costing about $89.7 million, which are expected to reduce potential dilution from conversions, and agreed to exchange about $165.9 million of its 2030 notes for about 40.7 million shares of common stock. The notes add debt and could dilute shareholders if converted, though the filing says the capped calls are expected to offset some of that dilution.
$850.0 million principal of 0.00% convertible senior notes due November 1, 2032; initial purchasers have a 13-day option for up to an additional $150,000,000
Initial conversion price of about $15.31 per share (65.3211 shares per $1,000 principal)
Capped call transactions cost about $89.7 million, with a cap price of $28.35, a 150% premium over the October 13, 2026 last sale price
Concurrent exchange of about $165.9 million of 1.75% 2030 notes for about 40.7 million shares of common stock
Enova International and Grasshopper Bancorp mutually terminated their December 2025 merger agreement on October 16, 2026. Enova made a $4,000,000 cash payment to Grasshopper, and neither party owes other fees or liabilities related to the agreement.
Merger agreement dated December 10, 2025, amended December 18, 2025, is now terminated effective October 16, 2026
Enova paid Grasshopper a $4,000,000 cash payment under the Mutual Termination Agreement and Release
No other fees or liabilities are owed by either party related to the merger agreement
Termination agreement is filed as Exhibit 10.1; General Counsel Sean Rahilly signed the report
SentinelOne completed a private offering of $1.25 billion of 0.00% convertible senior notes due October 1, 2031, with the $187.5 million over-allotment option exercised in full. The notes are unsecured and bear no regular interest, but they add debt, and conversion could dilute existing shareholders if the stock rises above the initial conversion price of about $31.21.
$1.25 billion of 0.00% convertible senior notes due October 1, 2031, including full exercise of the $187.5 million option
Initial conversion price of about $31.21 per share, a 30.0% premium over the $24.01 close on October 13, 2026
About $150.0 million of proceeds used to repurchase about 6.2 million Class A shares from note purchasers at $24.01 per share
Capped call transactions cost about $131.6 million, with a cap price of $48.02 per share, intended to reduce potential dilution
XTI Drones Holdings, a subsidiary of XTI Aerospace, missed $1.5 million in principal payments due September 30, 2026 on two seller promissory notes tied to its Drone Nerds and Anzu Robotics acquisitions, triggering events of default on October 11, 2026. The defaults also create cross-defaults under the subsidiary's $20.0 million JPMorgan Chase credit agreement, which the company says may let the lender terminate commitments and accelerate about $8.4 million of outstanding revolving loans. The company says it does not have enough liquidity to repay all amounts that could come due, and that the situation could materially harm its liquidity and financial condition.
Missed payments: $1,380,000 under the DN Note and $120,000 under the AR Note, due September 30, 2026; events of default occurred October 11, 2026
Outstanding principal on the two notes is about $4.51 million as of October 11, 2026; default interest rate is 9.25% per annum
Credit agreement with JPMorgan Chase Bank, N.A. has about $8.4 million of revolving loans outstanding as of October 16, 2026; no remedy notice received yet
Company agreed in principle with sellers on a temporary waiver subject to a signed agreement; no assurance a deal will be reached
Apollo Commercial Real Estate Finance, Inc. said it has notified the NYSE of its intent to voluntarily delist its common shares, with the last trading day expected on November 6, 2026. After delisting, the company plans to transfer its remaining assets and liabilities to a Maryland liquidating trust, distribute trust interests to stockholders one-for-one, and deregister with the SEC around November 9, 2026. Those trust interests will not be transferable or trade on any exchange, so shareholders will lose a market for their holdings.
Form 25 filing to remove the shares from NYSE listing expected on or about October 27, 2026
Last day of trading on the NYSE expected to be November 6, 2026
Company expects to deregister with the SEC on November 9, 2026
Beneficial interests in the Liquidating Trust distributed one-for-one to stockholders; they will not trade on the NYSE or any other exchange
Bridgeline Digital received a Nasdaq letter stating its common stock has not maintained the $1.00 minimum bid price for 30 consecutive business days ended October 13, 2026. The company has until April 12, 2027 to regain compliance by closing at or above $1.00 for at least ten consecutive business days, and the letter does not trigger immediate delisting. Shareholders should note that failure to regain compliance could lead to further Nasdaq action.
Nasdaq letter received October 14, 2026, citing Listing Rule 5550(a)(2) minimum bid price of $1.00 per share
Compliance deadline is April 12, 2027, a 180-calendar-day Initial Compliance Period
Company may be eligible for an additional 180-calendar-day period if it meets other listing standards and gives written notice of intent to cure
Letter does not result in immediate delisting from The Nasdaq Capital Market
NioCorp's majority-owned subsidiary Elk Creek Resources signed an Offtake Agreement with Traxys North America on October 13, 2026, replacing prior ferroniobium and scandium offtake agreements with Traxys. The deal gives Traxys take-or-pay purchase rights on 50% of annual ferroniobium output and exclusive marketing rights for 100% of other Elk Creek products, which matters to shareholders because it sets the sales framework for the project's planned output.
Agreement dated October 13, 2026, between Elk Creek Resources and Traxys North America LLC
Traxys to buy 50% of annual ferroniobium production on a take-or-pay basis, or 3,700 metric tonnes per year at Traxys' election
Term of 15 years from the Commercial Production Date, followed by two automatic one-year renewals
Either party may terminate if the Export-Import Bank of the United States has not given final approval of senior debt financing by December 31, 2027
High Roller Technologies said its Audit Committee concluded on October 15, 2026 that its unaudited financial statements for the quarters ended March 31 and June 30, 2026 should no longer be relied upon. The error involved approximately $1.0 million of warrant costs tied to a January 2026 registered direct offering; the correction is non-cash, does not affect revenue or cash, and would reduce the reported net loss, but the company also identified an additional material weakness in internal control over financial reporting. The company intends to file amended Forms 10-Q on October 16, 2026.
Q1 2026 net loss restated to $2.0 million, or $0.19 per share, from $3.0 million, or $0.29 per share
Six-month net loss through June 30, 2026 restated to $4.3 million, or $0.41 per share, from $5.3 million, or $0.50 per share
Approximately $1.0 million of warrant grant-date fair value was wrongly expensed as G&A instead of reducing additional paid-in capital
Amended 10-Q reports to be filed October 16, 2026; WithumSmith+Brown was briefed on the matters
Canopy Growth received a Nasdaq letter dated October 14, 2026, saying its common shares have traded below $1.00 for 30 consecutive business days. The Letter has no immediate effect on the Nasdaq listing, and the company has until April 12, 2027 to regain compliance, with a possible reverse stock split proposed to shareholders at an October 23, 2026 reconvened meeting.
Nasdaq Letter dated October 14, 2026 cites Listing Rule 5450(a)(1) minimum bid price requirement of $1.00 per share
Compliance period runs 180 calendar days to April 12, 2027; shares must close at or above $1.00 for at least ten consecutive business days
Share Consolidation Proposal would allow a ratio of one new share for every five to 15 old shares, set by the board, before October 23, 2027
Annual Meeting reconvenes Friday, October 23, 2026 after a lack of quorum on September 25, 2026; the company states no assurance of approval or price increase
IonQ entered into an underwriting agreement on October 14, 2026 with J.P. Morgan Securities LLC for a sale of 20.5 million common shares, 29.5 million pre-funded warrants and 100 million Series C warrants, with each share or pre-funded warrant offered with two Series C warrants at a combined price of $40.00. The offering closed on October 16, 2026. The filing shows the new shares and warrants add potential dilution for existing shareholders, and the Series C warrants can be exercised at $69.46 per share for up to seven years.
Offering closed October 16, 2026, after an underwriting agreement dated October 14, 2026 with J.P. Morgan Securities LLC as sole underwriter
Offered 20.5 million common shares and 29.5 million pre-funded warrants, each paired with two Series C warrants, at a combined price of $40.00
Series C warrants total 100 million, with an exercise price of $69.46 per share and a term through the seven-year anniversary of issuance
Warrants were issued under agreements dated October 16, 2026 with Continental Stock Transfer & Trust Company as warrant agent
CalciMedica's Chief Financial Officer, principal accounting officer and principal financial officer, Stephen Bardin, gave notice of his resignation on October 15, 2026, to pursue another professional opportunity. The resignation takes effect immediately after the company files its Form 10-Q for the quarter ended September 30, 2026, and the company said it was not due to any disagreement.
Stephen Bardin is CFO, principal accounting officer and principal financial officer.
Notice given October 15, 2026; effective immediately after the Q3 2026 Form 10-Q is filed.
Resignation is to pursue another professional opportunity, and the company states no disagreement was involved.
The filing names no successor or interim financial officer.
CID HoldCo agreed on October 9, 2026 to cancel about $368,107 in loans from its CEO, CFO/COO and CTO. In exchange, the company will pay about $37,075 in cash and issue 55,613 shares at a deemed price of $6.00 per share, and it has committed to issue 752,889 more shares to other creditors. The deal removes debt but adds new shares that can be sold after the April 15, 2027 lock-up ends, and the filing says it was approved as a related person transaction.
Executive loans totaled $368,107.25 as of October 9, 2026, including principal and unpaid interest.
Settlement terms: about $37,075 cash (roughly 10% of the debt) plus 55,613 shares at a deemed price of $6.00 per share.
As of October 15, 2026, the company committed to issue 752,889 shares to other creditors on similar terms.
Shares are locked up through April 15, 2027; the cash payment is due by December 31, 2026, and a resale registration statement is due by November 30, 2026.
Terra Innovatum Global N.V. dismissed KPMG Accountants N.V. as its independent auditor, effective October 12, 2026, and intends to engage MaloneBailey, LLP for fiscal 2026. The company says the change was not due to any disagreement with KPMG, but the filing notes material weaknesses in internal control over financial reporting that have not been remediated.
Audit Committee dismissed KPMG on October 9, 2026, effective October 12, 2026.
KPMG's report on fiscal 2025 financial statements contained no adverse opinion, disclaimer, or qualification.
Filing cites material weaknesses in internal control disclosed in the 2025 Form 10-K and the June 30, 2026 Form 10-Q, which have not been remediated.
MaloneBailey previously audited the company from April 29, 2025 to January 15, 2026; engagement is subject to client acceptance procedures.
Arrive AI Inc. said its independent auditor, Stephano Slack LLC, resigned effective October 13, 2026, and that the company engaged M&K CPAS, PLLC the same day to review its September 30, 2026 interim statements and audit fiscal 2026. Stephano Slack's prior audit report on fiscal 2025 included a going-concern explanatory paragraph and cited a material weakness in internal controls that was not fully remediated as of June 30, 2026, which matters for shareholders because it signals ongoing financial reporting and financial viability concerns.
Stephano Slack LLC resigned as auditor effective October 13, 2026; the company describes the separation as amicable.
M&K CPAS, PLLC was engaged on October 13, 2026 for the Q3 2026 review and the fiscal 2026 audit.
Fiscal 2025 audit report included a going-concern paragraph on substantial doubt about the company's ability to continue.
A material weakness tied to embedded derivatives and debt accretion led to 10-Q/A restatements filed April 15, 2026, and was not fully remediated as of June 30, 2026.
Health In Tech received two Nasdaq letters: one because it is not compliant with independent director and audit committee requirements after a director resigned, and one because its Class A shares closed below $1.00 for 30 consecutive business days. Neither letter has an immediate effect on the listing or trading of the stock, but the company faces cure deadlines and could face delisting if it fails to meet them.
Nasdaq letter dated October 14, 2026 cites non-compliance with independent director and audit committee rules after Sanjay Shrestha resigned on August 10, 2026; the Audit Committee has two members, and the company expects a new independent
Cure period for the board and audit committee rules ends at the earlier of the next annual meeting or August 10, 2027; the company must show compliance by February 8, 2027 if that meeting is held before then
Nasdaq letter dated October 12, 2026 cites a closing bid price below $1.00 for 30 consecutive business days; the company has until April 12, 2027 to regain compliance, which could require a reverse stock split
TOMI Environmental Solutions appointed Niroshan Srirathan, its interim chief financial officer, as permanent CFO, effective immediately, with the board action dated October 11, 2026. He has an annual base salary of $205,000 under an offer letter, and the company says the full letter will be filed as an exhibit to its next periodic report.
Board appointed Niroshan Srirathan, age 39, as permanent Chief Financial Officer on October 11, 2026, effective immediately.
Srirathan previously served as Interim CFO since May 16, 2026, and as Controller since May 4, 2026.
Annual base salary under the offer letter is $205,000.
The filing states no family relationships with directors or executive officers and no reportable related-person transactions.
Asure Software entered a $115 million senior credit facility with MUFG Bank on October 15, 2026, drawing the full $85.0 million term loan at closing and using proceeds to repay about $62.6 million owed under its MidCap credit agreement. The company also bought payroll processing assets from a southeastern US seller for $26.5 million, paying partly in newly issued common stock, which adds new debt and dilutes existing holders slightly.
$85.0 million term loan drawn October 15, 2026; $10.0 million revolver and $20.0 million delayed-draw term loan remain undrawn
Interest at Term SOFR plus 3.00%, initial three-month rate of 7.04249%; principal payments begin April 1, 2027, with maturity October 15, 2031
Paid $62.6 million to MidCap to retire the prior credit agreement and note, including $2.4 million in prepayment and termination fees
Acquisition price of $26.5 million included $13.5 million cash, a $3.0 million note, and 1,206,141 shares valued at $10.0 million
eHealth received a Nasdaq notice that its common stock closed below the $1.00 minimum bid price for 30 consecutive business days. The notice has no immediate effect, and the stock continues to trade on the Nasdaq Global Select Market under EHTH, but the company must regain compliance by April 12, 2027, or face possible delisting.
Notice received October 14, 2026, under Nasdaq Listing Rule 5450(a)(1)
Compliance period runs 180 calendar days, through April 12, 2027
Stock must close at or above $1.00 for at least 10 consecutive business days to regain compliance
Company may seek stockholder approval for a reverse stock split and says there is no assurance it will regain compliance
Callan JMB Inc. received a Nasdaq Staff determination on October 12, 2026 that it did not meet the terms of an extension to regain compliance with the $2,500,000 minimum stockholders' equity requirement, because it could not complete its capital raising initiatives. The company requested a hearing before a Nasdaq Hearings Panel on October 14, 2026, which stays the planned trading suspension, but the company says there is no assurance the Panel will grant continued listing.
Nasdaq Listing Rule 5550(b)(1) requires at least $2,500,000 in stockholders' equity for continued listing on The Nasdaq Capital Market.
Absent an appeal, trading in the common stock would have been suspended at the opening of business on October 21, 2026, and a Form 25-NSE would have been filed.
The company requested a hearing before a Nasdaq Hearings Panel on October 14, 2026, which stays the suspension and the Form 25-NSE pending the Panel's decision.
The filing states the Panel may not grant continued listing and the company may not regain compliance.
Fox Factory said preliminary third-quarter fiscal 2026 net sales and adjusted EBITDA came in below its guidance, and it lowered its fiscal 2026 outlook, including the divestiture of Marucci Sports, which closed September 25, 2026. CEO Michael Dennison stepped down and also left the Board, and director Douglas Grimm became interim CEO effective October 16, 2026, while the Board searches for a permanent CEO. Shareholders face lower expected results and a leadership change at the same time.
Q3 preliminary net sales of $336 million to $340 million, versus prior guidance of $355 million to $380 million; adjusted EBITDA of $38 million to $42 million, versus guidance of $46 million to $54 million (excluding about $12 million of IE
Fiscal 2026 net sales outlook lowered to $1.35 billion to $1.38 billion from $1.42 billion to $1.47 billion; adjusted EBITDA outlook of $140 million to $150 million excluding tariff refunds, versus prior $176 million to $196 million.
Michael Dennison stepped down as CEO and as a director effective October 15, 2026; Douglas Grimm was appointed Interim CEO effective October 16, 2026, with an annual base salary of $1,065,000.
The Board retained Heidrick & Struggles to search for a permanent CEO, and the company plans to hold its third-quarter earnings call on November 5, 2026.
SITE Centers Corp. notified the New York Stock Exchange on October 15, 2026 that it intends to voluntarily delist its common shares. The company plans to file a Form 25 on November 23, 2026, and expects the delisting to take effect before trading begins on December 4, 2026. The notice follows the sale of the company's interests in the Dividend Trust Portfolio joint venture.
Notice to NYSE provided October 15, 2026, under authority granted by the Board of Directors
Form 25 filing intended for November 23, 2026
Delisting expected to be effective before trading commences on December 4, 2026
Action follows the sale of the company's interests in the Dividend Trust Portfolio joint venture
On October 14, 2026, Copart's board approved a 10-year stock option for 20,000,000 shares for CEO A. Jayson Adair, granted outside the company's 2007 Equity Incentive Plan. The option cannot be exercised unless stockholders approve it at the 2026 Annual Meeting or a later special meeting, and it is forfeited if they do not. Shareholders may care because the award is large and is described as Adair's only substantive pay for the 10-year period, with a $1 annual salary and no expected bonus.
Option covers 20,000,000 shares in four tranches of 5,000,000 shares at $26.27, $35.03, $43.78 and $52.54 per share
Option has a 10-year term and first becomes exercisable on the 5th anniversary of the October 14, 2026 grant date, subject to continued service as CEO
Requires stockholder approval at the 2026 Annual Meeting or a special meeting after it; otherwise forfeited in full
Adair is expected to receive a $1 salary each year and no bonus or additional equity awards during the 10-year period
WidePoint Corporation's Chief Financial Officer, Robert George, tendered his resignation on October 9, 2026, citing personal and family reasons and stating no disagreement with the company. The resignation takes effect when the Form 10-Q for the quarter ended September 30, 2026 is filed, and he will assist in a non-officer role during the transition.
Robert George resigned as Chief Financial Officer; notice dated October 9, 2026
Resignation effective upon filing of the Form 10-Q for the quarter ended September 30, 2026
Resignation is for personal and family reasons, not a disagreement with the company
Mr. George will continue in a non-officer capacity to support an orderly transition
Copart completed its acquisition of ACV Auctions on October 16, 2026, through a merger that followed a tender offer at $10.50 per share in cash. ACV shares have stopped trading on the New York Stock Exchange, and ACV will operate as an independent Copart subsidiary led by its existing leadership team. The filing does not disclose the total deal value or any financial effect on Copart.
Tender offer price was $10.50 per share in cash, subject to withholding taxes.
116,818,409 ACV shares were validly tendered, about 68.43% of shares outstanding, when the offer expired at 5:00 p.m. Eastern Time on October 15, 2026.
Remaining ACV shares were converted into the right to receive the same $10.50 cash price in the merger completed October 16, 2026.
ACV shares have ceased trading on the New York Stock Exchange.
On October 15, 2026, Sanara MedTech and MiMedx each received a Second Request from the Federal Trade Commission as part of its review of the proposed merger in which Sanara would become a wholly-owned subsidiary of MiMedx. Under the Hart-Scott-Rodino Act, the Second Request extends the waiting period until 30 days after the parties substantially comply, so closing is likely to take longer, and completion still depends on regulatory and other conditions.
FTC issued a Second Request to Sanara and MiMedx on October 15, 2026.
The Second Request extends the HSR Act waiting period until 30 days after substantial compliance, unless extended or terminated earlier.
Completion remains subject to HSR waiting period expiration and other closing conditions in the Merger Agreement.
The filing does not state a expected closing date or any financial figures for the deal.
Union Pacific said Chief Financial Officer Jennifer Hamann will retire in early 2027 after 35 years with the company, and she will keep her current responsibilities until then. The company has not yet named a successor and said it will announce succession plans and further transition details at a later date.
Jennifer L. Hamann, Executive Vice President and Chief Financial Officer, plans to retire effective in early 2027.
Hamann joined Union Pacific in 1992 and was named chief financial officer in January 2020.
Union Pacific said it will announce succession plans and additional transition details at a later date.
The filing reports no financial results; the announcement is furnished as Exhibit 99.1.
MiMedx and Sanara MedTech each received a Second Request from the Federal Trade Commission on October 15, 2026, as part of the FTC's review of their proposed merger. The request extends the Hart-Scott-Rodino waiting period until 30 days after the parties substantially comply, which could delay closing; the filing gives no expected timing.
FTC issued Second Requests to MiMedx and Sanara on October 15, 2026.
Second Request extends the HSR Act waiting period until 30 days after substantial compliance, unless extended voluntarily or ended earlier by the FTC.
Completion still depends on HSR waiting period expiration and other closing conditions; MiMedx says it continues to work constructively with the FTC.
Erasca, Inc. said its Chief Operating Officer, Nicholas (Nik) Chetwyn, Ph.D., will leave the company, with employment ending November 2, 2026. The company said duties overseen by the COO are moving to other leadership team members to streamline its reporting structure. The filing does not disclose a successor or any financial terms of the departure.
Chief Operating Officer Nicholas (Nik) Chetwyn, Ph.D., employment terminates effective November 2, 2026
Decision made October 15, 2026, as part of a leadership realignment
COO responsibilities are transitioning to other members of the leadership team
Filing does not name a replacement or disclose separation terms
MiniMed completed its exchange offer with Medtronic on October 15, 2026, and Medtronic no longer holds any MiniMed common stock. The same day, four directors resigned from the MiniMed board, and Amy Bricker was appointed to fill one vacancy as the board was reduced from 11 to eight seats.
Medtronic accepted 55,032,401 Medtronic ordinary shares in exchange for 252,813,348 newly issued MiniMed common shares; the offer was 5.4x subscribed.
Medtronic no longer owns any MiniMed common stock, and MiniMed states it is now a fully independent company.
Linnea Burman, Scott Cundy, Laura Mauri and Matthew R. Walter resigned from the board effective October 15, 2026; Amy Bricker joined as a Class II director.
Odyssey Marine Exploration said the SEC declared its Form S-4 registration statement for the proposed merger with American Ocean Minerals Corporation effective on October 15, 2026. The company also announced a 1-for-25 reverse stock split, which it says is intended to increase the trading price of its common stock and reduce stockholder transaction costs, and which is a condition to certain investors providing financing for the combined company.
Registration statement declared effective October 15, 2026; special stockholder meeting set for December 2, 2026, at 10:00 a.m. Eastern Time
1-for-25 reverse split: record date October 26, 2026, effective October 28, 2026, with split-adjusted trading beginning October 29, 2026
Shares outstanding expected to fall from about 58.6 million to about 2.3 million; authorized shares rise from 75 million to 82 million on October 28, 2026
The board adopted a 2026 Equity Incentive Plan on October 15, 2026, subject to stockholder approval at the special meeting
Emergent BioSolutions said Chief Financial Officer Richard Lindahl will step down as principal financial and accounting officer effective December 31, 2026, and retire on March 31, 2027, after serving as an advisor. Frank Vargo, the company's Vice President and Treasurer, will become Interim Chief Financial Officer on January 1, 2027. The filing reports no financial results, so the change is a leadership transition rather than a change in reported performance.
Richard Lindahl steps down as principal financial and accounting officer effective December 31, 2026, and serves as an advisor until retiring on March 31, 2027.
Frank Vargo, Vice President and Treasurer, becomes Interim Chief Financial Officer on January 1, 2027.
Vargo's interim pay is an additional $3,850 per pay period on top of his base salary of $328,000.
Lindahl will help prepare the Form 10-K for the year ending December 31, 2026.
Fractyl Health reported topline six-month results from the Pivotal Cohort of its REMAIN-1 study of the Revita DMR System, a randomized, double-blind, sham-controlled trial. The company said Revita met its six-month co-primary endpoint, with participants retaining about 80% of GLP-1-induced weight loss versus 67% for sham, and the company plans a De Novo marketing application to the FDA in late Q4 2026.
Six-month co-primary endpoint met in the mITT population (N=308) with p=0.0023; weight regain of 5.1% for Revita versus 8.2% for sham
Post hoc analysis: participants receiving 20 cm or more of ablation had a mean weight regain of 3.8% (n=47); the second co-primary endpoint at 12 months is expected in Q1 2027
No device- or procedure-related serious adverse events, no deaths, and no unanticipated adverse device effects as of the September 24, 2026 data cut-off
Potential U.S. De Novo submission planned for late Q4 2026; potential U.S. launch in early 2028 if authorized
Citizens Financial Group reported third quarter 2026 net income of $636 million, up 29% from a year earlier, with diluted EPS of $1.41 compared with $1.05 in third quarter 2025. The board raised the quarterly common dividend to $0.52 per share and increased share repurchase capacity to $1.95 billion, which matters to shareholders because it returns more capital to them, though tangible book value per share fell 6.6% in the quarter.
Net income of $636 million, up 29% year over year and 8% from second quarter 2026; diluted EPS of $1.41 versus $1.30 in second quarter 2026 and $1.05 in third quarter 2025.
Quarterly common dividend raised to $0.52 per share, an increase of $0.06, or 13%, payable November 13, 2026 to holders of record on October 30, 2026.
Share repurchase capacity increased to $1.95 billion, $1.3 billion above the $650 million remaining under the June 2025 authorization.
Tangible book value per common share was $35.78, down 6.6% from second quarter 2026, which the company attributed to higher long-term rates on its investment securities and swap portfolios.
Truist reported third quarter 2026 GAAP diluted EPS of $0.56, down from $1.23 in the second quarter and $1.04 a year earlier, mainly due to a $1.4 billion pre-tax loss on the sale of available-for-sale securities. Excluding selected items, adjusted diluted EPS was $1.16, up 12% from the third quarter of 2025, and total revenue on the GAAP basis fell to $3.75 billion from $5.27 billion. The company also agreed on October 14, 2026 to sell $7.7 billion of unsecured consumer loans tied to its LightStream platform to Carlyle Group Inc.
GAAP diluted EPS was $0.56 versus $1.23 in 2Q26 and $1.04 in 3Q25; adjusted diluted EPS was $1.16
Noninterest income was $84 million, including a $1.4 billion pre-tax securities loss and a $66 million loss on the RAC loan sale
Agreement signed October 14, 2026 to sell $7.7 billion of unsecured consumer loans, substantially all assets of LightStream, to Carlyle Group Inc.
Truist repurchased $1.2 billion of common stock and declared dividends of $0.52 per share in the quarter; preliminary CET1 ratio was 10.7%
International Seaways agreed to acquire Bruton Limited, a Bermuda tanker company valued at about $370 million, through a share exchange with holders of about 50.5% of Bruton's shares and a later merger. The same release gave preliminary third-quarter 2026 results, with shipping revenues of $480-$490 million and net income of $340-$350 million, including a gain of about $50 million on a vessel sale, while blended spot earnings fell from the second quarter but rose from a year earlier. Shareholders should note that the Bruton merger is subject to a Bruton shareholder vote and that the share issuance will dilute existing holders.
Bruton is valued at about $370 million; holders of about 50.5% of its shares will exchange them for 0.05190 Seaways shares each, with that exchange expected to close on or about October 20, 2026.
Bruton holders of 10,000 or fewer shares will receive $6.3044 cash per share; the merger is expected to close after Bruton's special meeting on or about October 30, 2026, and either party may terminate if it has not closed by November 15, 2
Preliminary Q3 2026: shipping revenues of about $480-$490 million, net income of about $340-$350 million including a gain of about $50 million on a 2012-built Suezmax sale, and total liquidity of about $965 million.
Seaways expects to issue about 3.12 million shares, about 96% of the total consideration; blended spot earnings were about $68,000 per day in Q3 versus $79,000 in Q2 2026 and $29,000 in Q3 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.